Leaders in Pharmaceutical Business Intelligence (LPBI) Group

12:00AM – 9/30/2014: Oncology I – Building the Cancer Focused Biotech @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

Reporter: Aviva Lev-Ari, PhD, RN

 

Real Time Media Conference Coverage  –  Business and Scientific Channels by: http://pharmaceuticalintelligence.com

Co-Chaired by: 

• Esteban Pombo-Villar, COO, Oxford BioTherapeutics

– What is Big Pharma interested in?

– Underlying biology precedes the relations

– Other experience by Panelist

– Companion diagnostics

– The idea is the starting point — before the infrastructure

• Katya Smirnyagina, Partner, Capricorn Venture Partners

What data gets VCs attention?

Panelists: N=9

• Bernhard Sixt, CEO, ImmunID

– unproven biomarker, testing, sign off a test is a nightmare, Commercialization of the biomarker ImmunID has a test for predicting the response of immune inhibitors. Immunocheck for diagnostics

• Carlos Buesa, CEO, ORYZON

Compounds used for Leukemia, data was key for Big Pharma, Leader in the fields, assets, VCs, Roche offered Partnership, collaborations with teams of Roche, knowledge of the biology by the start up infrastructure of Big Pharma was a must

• John Haurum, CEO, F-Star

– biology behind target focus without understanding the Biology

– IP license agreement: Asset centered vehicle – all portfolio immunology and oncology – operations based in UK, exclusive rights to 23 oncology compounds, broaden the scope of the tax effective exit potential first company with corporate base, investor based

– start up collaboration, generate trust

• Guillaume Vignon, Director of Global Business Development and Licensing, EMD Serono

Class of Molecules which are more risky to Pharma, investing in format in treatment

Corporate Venture Fund – rational for Biologics investment risk component, this fund was used for funding and provide access to Scientists of Merck,

knowledge and sponsors to invest in the company by investment from a Big Pharma, convincing the management of Merck,

– Pharma is investing in University Collaborations — it is there more is coming

• Philip Serlin, CEO, BioLineRx Peter Sandor, VP, Global Marketing, TA Head Oncology, Amgen

• Peter Sandor, VP Global TA Head Oncology, Amgen

Best medicine to the Patient, value creation to the patient by differentiation of efficacy, Factors: Platform late stage antibodies, small molecules

• Robert H. Pierce, CMO, OncoSec

Cambridge, MA validate immunology mouth Program, identified by Merck, program killed , Open minds to conceptual breakthroughs, Scientists and data for translational BETTER models, not the are

•  Stephen Sands, Commercial Lead Oncology/Immunology Hoffmann-La Roche AG

People buy people first, Human Capital is the critical component for relationships, Gap identification in the Portfolio, strengthening the diverse portfolio, identification of new talent.

– Clinical data, rational discussion is a must

– Phase III failure — due to rational not fully exploited

• Vladimir Cmiljanovic, CEO, Piqur Therapeutics AG

Building a Team led by a Postdoc based in Basel. Strong financial structure, register the drug by a Global patent. Small Biotech, founders of Genetech, Amgen, noted the Scientific differentiation.inhibition very short of PKT vs competitors, discover scaffold for the drug, compound crosses brain barriers — for Brain Tumors, define the differentiation – convinces investors

– lacking know how in the drug developer vs. University structure that has the Science developed thus, ecosystem and collaboration cross organizations

QUESTION

AstraZeneca Phase III failures

 

#startup#biotech #CancerTherapy #pharmanews

@BiotechNews